Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults

Leland Metheny, Natalie S. Callander, Aric C. Hall, Mei Jei Zhang, Khalid Bo-Subait, Hai Lin Wang, Vaibhav Agrawal, A. Samer Al-Homsi, Amer Assal, Ulrike Bacher, Amer Beitinjaneh, Nelli Bejanyan, Vijaya Raj Bhatt, Chris Bredeson, Michael Byrne, Mitchell Cairo, Jan Cerny, Zachariah DeFilipp, Miguel Angel Diaz Perez, César O. FreytesSiddhartha Ganguly, Michael R. Grunwald, Shahrukh Hashmi, Gerhard C. Hildebrandt, Yoshihiro Inamoto, Christopher G. Kanakry, Mohamed A. Kharfan-Dabaja, Hillard M. Lazarus, Jong Wook Lee, Sunita Nathan, Taiga Nishihori, Richard F. Olsson, Olov Ringdén, David Rizzieri, Bipin N. Savani, Mary Lynn Savoie, Sachiko Seo, Marjolein van der Poel, Leo F. Verdonck, John L. Wagner, Jean A. Yared, Christopher S. Hourigan, Partow Kebriaei, Mark Litzow, Brenda M. Sandmaier, Wael Saber, Daniel Weisdorf, Marcos de Lima

Resultado de la investigación: Articlerevisión exhaustiva

9 Citas (Scopus)


Patients who develop therapy-related myeloid neoplasm, either myelodysplastic syndrome (t-MDS) or acute myelogenous leukemia (t-AML), have a poor prognosis. An earlier Center for International Blood and Marrow Transplant Research (CIBMTR) analysis of 868 allogeneic hematopoietic cell transplantations (allo-HCTs) performed between 1990 and 2004 showed a 5-year overall survival (OS) and disease-free survival (DFS) of 22% and 21%, respectively. Modern supportive care, graft-versus-host disease prophylaxis, and reduced-intensity conditioning (RIC) regimens have led to improved outcomes. Therefore, the CIBMTR analyzed 1531 allo-HCTs performed in adults with t-MDS (n = 759) or t-AML (n = 772) between and 2000 and 2014. The median age was 59 years (range, 18 to 74 years) for the patients with t-MDS and 52 years (range, 18 to 77 years) for those with t-AML. Twenty-four percent of patients with t-MDS and 11% of those with t-AML had undergone a previous autologous (auto-) HCT. A myeloablative conditioning (MAC) regimen was used in 49% of patients with t-MDS and 61% of patients with t-AML. Nonrelapse mortality at 5 years was 34% (95% confidence interval [CI], 30% to 37%) for patients with t-MDS and 34% (95% CI, 30% to 37%) for those with t-AML. Relapse rates at 5 years in the 2 groups were 46% (95% CI, 43% to 50%) and 43% (95% CI, 40% to 47%). Five-year OS and DFS were 27% (95% CI, 23% to 31%) and 19% (95% CI, 16% to 23%), respectively, for patients with t-MDS and 25% (95% CI, 22% to 28%) and 23% (95% CI, 20% to 26%), respectively, for those with t-AML. In multivariate analysis, OS and DFS were significantly better in young patients with low-risk t-MDS and those with t-AML undergoing HCT with MAC while in first complete remission, but worse for those with previous auto-HCT, higher-risk cytogenetics or Revised International Prognostic Scoring System score, and a partially matched unrelated donor. Relapse remains the major cause of treatment failure, with little improvement seen over the past 2 decades. These data mandate caution when recommending allo-HCT in these conditions and indicate the need for more effective antineoplastic approaches before and after allo-HCT.

Idioma originalEnglish (US)
Páginas (desde-hasta)923.e1-923.e12
PublicaciónTransplantation and Cellular Therapy
EstadoPublished - nov 2021

ASJC Scopus subject areas

  • Transplantation
  • Molecular Medicine
  • Hematology
  • Immunology and Allergy
  • Cell Biology


Profundice en los temas de investigación de 'Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults'. En conjunto forman una huella única.

Citar esto